Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers API solutions, such as small molecules, highly potent, carbapenems, glycans, peptides, oligonucleotides, and therapeutic enzymes; GMP, non-GMP, asymchem lab facilities and capabilities, commercial manufacturing, clinical man… Read more
Asymchem Laboratories Tian Jin Co Ltd (002821) - Net Assets
Latest net assets as of September 2025: CN¥17.36 Billion CNY
Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) has net assets worth CN¥17.36 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥19.81 Billion) and total liabilities (CN¥2.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥17.36 Billion |
| % of Total Assets | 87.65% |
| Annual Growth Rate | 30.26% |
| 5-Year Change | 181.3% |
| 10-Year Change | 1699.59% |
| Growth Volatility | 37.05 |
Asymchem Laboratories Tian Jin Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Asymchem Laboratories Tian Jin Co Ltd (2011–2024)
The table below shows the annual net assets of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥16.86 Billion | -3.70% |
| 2023-12-31 | CN¥17.51 Billion | +11.56% |
| 2022-12-31 | CN¥15.70 Billion | +24.46% |
| 2021-12-31 | CN¥12.61 Billion | +110.36% |
| 2020-12-31 | CN¥5.99 Billion | +96.83% |
| 2019-12-31 | CN¥3.05 Billion | +21.31% |
| 2018-12-31 | CN¥2.51 Billion | +16.50% |
| 2017-12-31 | CN¥2.16 Billion | +17.57% |
| 2016-12-31 | CN¥1.83 Billion | +95.62% |
| 2015-12-31 | CN¥937.02 Million | +19.34% |
| 2014-12-31 | CN¥785.17 Million | +14.44% |
| 2013-12-31 | CN¥686.10 Million | +12.83% |
| 2012-12-31 | CN¥608.06 Million | +12.13% |
| 2011-12-31 | CN¥542.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Asymchem Laboratories Tian Jin Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10070.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥8.08 Billion | 47.95% |
| Common Stock | CN¥367.72 Million | 2.18% |
| Other Components | CN¥8.40 Billion | 49.86% |
| Total Equity | CN¥16.85 Billion | 100.00% |
Asymchem Laboratories Tian Jin Co Ltd Competitors by Market Cap
The table below lists competitors of Asymchem Laboratories Tian Jin Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neway Valve suzhou Co Ltd
SHG:603699
|
$2.99 Billion |
|
SoundHound AI Inc
NASDAQ:SOUN
|
$2.99 Billion |
|
Q2 Holdings
NYSE:QTWO
|
$2.99 Billion |
|
Redwood Trust, Inc.
NYSE:RWTP
|
$2.99 Billion |
|
WD-40 Company
NASDAQ:WDFC
|
$2.98 Billion |
|
Thunder Software Technology Co Ltd
SHE:300496
|
$2.98 Billion |
|
Far Eastern New Century Corp
TW:1402
|
$2.98 Billion |
|
Alm. Brand A/S
PINK:ABDBY
|
$2.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Asymchem Laboratories Tian Jin Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,479,716,341 to 16,845,385,169, a change of -634,331,172 (-3.6%).
- Net income of 948,950,038 contributed positively to equity growth.
- Dividend payments of 641,939,094 reduced retained earnings.
- Share repurchases of 1,238,410,632 reduced equity.
- Other factors increased equity by 297,068,516.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥948.95 Million | +5.63% |
| Dividends Paid | CN¥641.94 Million | -3.81% |
| Share Repurchases | CN¥1.24 Billion | -7.35% |
| Other Changes | CN¥297.07 Million | +1.76% |
| Total Change | CN¥- | -3.63% |
Book Value vs Market Value Analysis
This analysis compares Asymchem Laboratories Tian Jin Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 48.80x to 2.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥2.02 | CN¥98.70 | x |
| 2012-12-31 | CN¥2.23 | CN¥98.70 | x |
| 2013-12-31 | CN¥2.50 | CN¥98.70 | x |
| 2014-12-31 | CN¥2.96 | CN¥98.70 | x |
| 2015-12-31 | CN¥3.51 | CN¥98.70 | x |
| 2016-12-31 | CN¥6.84 | CN¥98.70 | x |
| 2017-12-31 | CN¥6.42 | CN¥98.70 | x |
| 2018-12-31 | CN¥7.79 | CN¥98.70 | x |
| 2019-12-31 | CN¥9.43 | CN¥98.70 | x |
| 2020-12-31 | CN¥18.26 | CN¥98.70 | x |
| 2021-12-31 | CN¥36.94 | CN¥98.70 | x |
| 2022-12-31 | CN¥42.65 | CN¥98.70 | x |
| 2023-12-31 | CN¥48.23 | CN¥98.70 | x |
| 2024-12-31 | CN¥47.75 | CN¥98.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Asymchem Laboratories Tian Jin Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.35%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.15x
- Recent ROE (5.63%) is below the historical average (13.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 12.89% | 16.11% | 0.51x | 1.58x | CN¥14.65 Million |
| 2012 | 10.72% | 14.20% | 0.51x | 1.47x | CN¥4.07 Million |
| 2013 | 11.86% | 13.77% | 0.59x | 1.45x | CN¥11.75 Million |
| 2014 | 13.65% | 14.21% | 0.68x | 1.42x | CN¥27.24 Million |
| 2015 | 17.42% | 18.49% | 0.65x | 1.44x | CN¥65.42 Million |
| 2016 | 14.41% | 22.91% | 0.45x | 1.39x | CN¥77.30 Million |
| 2017 | 16.59% | 23.98% | 0.54x | 1.28x | CN¥135.53 Million |
| 2018 | 17.06% | 23.34% | 0.58x | 1.27x | CN¥177.24 Million |
| 2019 | 18.19% | 22.51% | 0.65x | 1.23x | CN¥249.31 Million |
| 2020 | 12.01% | 22.95% | 0.44x | 1.19x | CN¥120.28 Million |
| 2021 | 8.48% | 23.08% | 0.31x | 1.20x | CN¥-191.73 Million |
| 2022 | 21.10% | 32.27% | 0.56x | 1.17x | CN¥1.74 Billion |
| 2023 | 12.98% | 28.99% | 0.40x | 1.13x | CN¥520.84 Million |
| 2024 | 5.63% | 16.35% | 0.30x | 1.15x | CN¥-735.59 Million |
Industry Comparison
This section compares Asymchem Laboratories Tian Jin Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Asymchem Laboratories Tian Jin Co Ltd (002821) | CN¥17.36 Billion | 12.89% | 0.14x | $2.98 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |